Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified potential new adverse drug reaction signals for erlotinib, used in lung and pancreatic cancer treatment, by analyzing a large dataset of case reports, indicating further clinical studies are necessary to confirm these findings.

This study found that the antiseizure activity of midazolam primarily occurs through synaptic GABA-A receptors, with no significant involvement of endogenous neurosteroids or extrasynaptic receptors.

This review discusses the use of acitretin, a retinoid approved since 1997, for various forms of psoriasis and its potential benefits in combination therapy, but reports no new clinical findings.

This study explored the solubility and crystal structure of GI197111X, a 5-alpha reductase inhibitor for androgenetic alopecia, finding its solubility in Capmul MCM suitable for a soft gel dosage form.

A test for nail fungus was most accurate with PAS stain, low-dose spironolactone helped two-thirds of acne patients, metformin reduced symptoms of HIV-related fat distribution changes with some side effects, and skin examination with dermoscopy was better at detecting abnormal moles, while temporary tattoos can cause skin reactions.

This review highlights that although advancements in alopecia areata treatments, such as Janus kinase inhibitors and combination therapies, show promise, further research is necessary to validate their long-term safety and efficacy.

In this study, daily treatment with ritlecitinib for up to 24 months led to significant reductions in high-severity alopecia areata SALT scores among patients aged ≥12 years, including those with severe forms such as alopecia totalis and universalis.

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

This study reports cases of androgenetic alopecia patients with depigmented macules on sun-exposed scalp areas, suggesting potential ultraviolet-induced scalp leukoderma not covered in existing dermatology texts.

This study reports that ZD1839 (Iressa), an anticancer drug, was associated with acneiform eruptions and hair growth abnormalities due to its inhibition of epidermal growth factor receptor signaling in the skin.

In this article, the authors reported that calcipotriol/betamethasone dipropionate aerosol foam significantly improved scalp psoriasis symptoms in three patients by reducing itching and improving flaky patches within a four-week treatment period, confirming its efficacy and enhanced skin penetration compared to older formulations.

This study found that a polyherbal sunscreen cream, F4, containing Camellia sinensis, Vitis vinifera, and Silybum marianum extracts demonstrated strong antioxidant and photoprotective properties, similar to synthetic sunscreens.

Switching Janus kinase inhibitors helped some patients with severe alopecia areata regrow hair, but insurance issues can worsen the condition.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

This article reviews 12 newly approved drugs with pediatric indications from 2001, discussing their clinical importance for general pediatricians, but reports no new clinical results.

A new microneedle patch effectively and safely treats alopecia areata.

In this prospective study, ritlecitinib effectively reduced hair loss in patients with severe alopecia areata, with 43.3% of participants achieving a 20 or lower SALT score by week 24, and showed a good midterm safety profile.

In this study, researchers analyzed lurasidone's risk profile for treating schizophrenia and bipolar depression, identifying unlisted adverse reactions like hypersexuality, restless leg syndrome, thrombocytopenia, and telogen effluvium, which show probable or possible correlations with the drug.

In this study, vemurafenib was associated with a wide range of cutaneous side effects in patients with advanced melanoma, including photosensitivity and various skin and hair changes, necessitating regular dermatological management.

This CADTH recommendation advises that Olumiant should be publicly reimbursed for treating severe alopecia areata in adults, provided conditions such as a 50% scalp hair loss and specific prescribing criteria are met.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

In this study, a 14-year-old girl developed Malassezia folliculitis and seborrheic dermatitis after starting trametinib, which improved with itraconazole treatment. The research underscores the importance of recognizing trametinib-related skin reactions and suggests managing them with antifungal therapy without necessarily discontinuing the medication.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

In this study, candidate compound 39 demonstrated potent androgen receptor antagonism and faster hair-growth efficacy in a mouse model compared to pyrilutamide, while maintaining favorable safety and pharmacokinetic profiles, suggesting potential for topical use in androgenic alopecia.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.